Skip to main content

Moleculin Biotech, Inc.

corporate_fare Company Profile

Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed MBRX - Latest Insights

MBRX
Apr 23, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
MBRX
Apr 15, 2026, 11:40 AM EDT
Filing Type: 8-K
Importance Score:
9
MBRX
Apr 14, 2026, 4:56 PM EDT
Filing Type: 424B3
Importance Score:
9
MBRX
Mar 27, 2026, 4:01 PM EDT
Filing Type: S-3
Importance Score:
9
MBRX
Mar 23, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
MBRX
Mar 19, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
MBRX
Mar 19, 2026, 8:36 AM EDT
Source: GlobeNewswire
Importance Score:
8
MBRX
Mar 19, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
MBRX
Mar 18, 2026, 4:06 PM EDT
Filing Type: 10-K
Importance Score:
9
MBRX
Mar 09, 2026, 3:58 PM EDT
Filing Type: DEF 14A
Importance Score:
8
MBRX
Feb 27, 2026, 2:09 PM EST
Filing Type: PRE 14A
Importance Score:
8
MBRX
Feb 20, 2026, 8:50 AM EST
Filing Type: 8-K
Importance Score:
9
MBRX
Feb 18, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
9
MBRX
Feb 17, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
MBRX
Feb 05, 2026, 11:55 AM EST
Filing Type: 8-K
Importance Score:
8
MBRX
Jan 20, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
MBRX
Jan 13, 2026, 8:55 AM EST
Filing Type: 8-K
Importance Score:
9
MBRX
Jan 12, 2026, 8:36 AM EST
Filing Type: 8-K
Importance Score:
8
MBRX
Jan 07, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
MBRX
Jan 02, 2026, 4:01 PM EST
Filing Type: DEF 14A
Importance Score:
8